Stenosis of arteriovenous fistula Circulatory System Arteriovenous fistula
Conditions
Interventions
Current interventions as of 03/03/2008:
HD patients:
40 minutes of far-infrared therapy during the second and the subsequent sessions of haemodialysis three times a week (TIW) for a duration of one
Sponsors
National Science Council (Taiwan)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Current inclusion criteria as of 03/03/2008: HD Patients: 1. Are receiving four hours of maintenance haemodialysis (HD) therapy three times weekly for at least six months 2. Are using a AVF or AV graft as the present vascular access for more than six months, without interventions within the previous three months Both HD and non-HD ESRD patients: 1. Are without fever or clinical signs of active infection 2. Creation of AVF with the standardised surgical procedures of venous end-to-arterial side anastomosis or AV graft with loop conformation by cardiovascular surgeons in our hospital in the upper extremity 3. Are between 20 and 80 years of age, both genders Previous inclusion criteria: Patients: 1. Are receiving 4 hours of maintenance haemodialysis (HD) therapy three times weekly for at least six months 2. Are using a native AVF as the present vascular access for more than six months, without interventions within the last three months 3. Are without fever or clinical signs of active infection 4. Creation of AVF by cardiovascular surgeons in our hospital with the standardised surgical procedures of venous end-to-arterial side anastomosis in the upper extremity 5. Are between 20 and 80 years of age, both genders
Exclusion criteria
Exclusion criteria: Current exclusion criteria as of 03/03/2008: Patients use Perm catheter as vascular access for haemodialysis. Previous exclusion criteria: Patients use AV graft or Perm catheter as vascular access for haemodialysis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Current primary outcome measure as of 03/03/2008: Unassisted patency of vascular access. Previous primary outcome measures: 1. Soluble ICAM-1 and VCAM-1 by specific enzyme-linked immunosorbent assay (ELISA) (Diaclone, Besançon, France) 2. High sensitivity C-reactive protein (hsCRP) Blood samples will be collected every three months for a study period of one year. | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measure as of 03/03/2008: 1. Blood samples were analysed for the following items every three months: 1.1. Soluble intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) 1.2. High sensitivity C-reactive protein (hsCRP) 2. Haemodynamic parameters (access flow, cardiac output and total peripheral resistance) will be measured by HD-02 monitor every three months in HD patients and by Doppler ultrasonography in non-HD ESRD patients Previous secondary outcome measure: Access blood flow; blood samples will be collected every three months for a study period of one year. | — |
Countries
China, Taiwan
Outcome results
None listed